Medication-related osteonecrosis of the jaw-A case report and literature review
Article Sidebar
Main Article Content
Abstract
Osteoporosis is a skeletal disease caused by changes in the structure of the human skeleton, resulting in fragile and easily fractured bones. Because it is more common in postmenopausal women or the elderly, fractures may cause disability in the elderly, resulting in reduced quality of life, bedridden, or increased mortality. Therefore, the treatment of osteoporosis is one of the important issues in today’s aging society. In addition, diseases such as bone metastasis of cancer and multiple myeloma also need to be paid attention to. Drugs for the treatment of osteoporosis have been widely used in the prevention and treatment of osteoporosis because of their inhibitory effect on osteoclast activity, and even become the first-choice drug for bone metastases of some malignant tumors. Drugs for the treatment or prevention of osteoporosis can inhibit osteoclasts, and can also be used to treat hypercalcemia complications of malignant tumors or bone-related systemic diseases. For example, bisphosphonates or monoclonal antibody preparations (eg: Denosumab, Romosozumab, etc.) can resist bone resorption. However, in recent years, the literature pointed out that patients using anti-bone resorption drugs may have adverse reactions to maxillofacial osteonecrosis. Medication-Related Osteonecrosis of the Jaw (MRONJ) may occur in patients with osteoporosis and tumors. Bisphosphonates or synthetic human monoclonal antibodies can inhibit bone resorption and are currently the most commonly used drugs for the treatment of osteoporosis in the world. The literature for nearly 20 years has shown that long-term use of such antiresorptive drugs increases the risk of osteonecrosis of the jaw in the oral cavity. Therefore, MRONJ is still a complication that we must pay attention to. Once MRONJ occurs, it is recommended to refer to an oral surgeon immediately; the current clinical treatment methods include the use of antibacterial mouthwash and drugs to control pain in mild cases, and antibiotics for infection control in moderate cases.
Downloads
Article Details
Copyright (c) 2023 Chen C, et al.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Aguirre JI, Castillo EJ, Kimmel DB. Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (MRONJ). Bone. 2021 Dec;153:116168. doi: 10.1016/j.bone.2021.116168. Epub 2021 Sep 3. PMID: 34487892; PMCID: PMC8478908.
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022 May;80(5):920-943. doi: 10.1016/j.joms.2022.02.008. Epub 2022 Feb 21. PMID: 35300956.
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7. doi: 10.1016/s0278-2391(03)00720-1. PMID: 12966493.
Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008 May;42(5):841-7. doi: 10.1016/j.bone.2008.01.003. Epub 2008 Jan 18. PMID: 18314405.
Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab. 2014 Aug;99(8):2729-35. doi: 10.1210/jc.2013-4119. Epub 2014 Apr 23. PMID: 24758181.
Aguirre JI, Castillo EJ, Kimmel DB. Preclinical models of medication-related osteonecrosis of the jaw (MRONJ). Bone. 2021 Dec;153:116184. doi: 10.1016/j.bone.2021.116184. Epub 2021 Sep 11. PMID: 34520898; PMCID: PMC8743993.
Marx RE. Understanding Drug-Induced Osteonecrosis of the Jaws. In: Drug-Induced Osteonecrosis of the Jaws: How to Diagnose, Prevent, and Treat It. 1st ed. Quintessence Publishing. 2022: 3–8.
Dunphy L, Salzano G, Gerber B, Graystone J. Medication-related osteonecrosis (MRONJ) of the mandible and maxilla. BMJ Case Rep. 2020 Jan 5;13(1):e224455. doi: 10.1136/bcr-2018-224455. Corrected and republished in: Drug Ther Bull. 2020 Nov;58(11):172-175. PMID: 31907213; PMCID: PMC6954753.
Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):61-70. doi: 10.1016/j.joms.2009.01.007. PMID: 19371816.
AlDhalaan NA, BaQais A, Al-Omar A. Medication-related Osteonecrosis of the Jaw: A Review. Cureus. 2020 Feb 10;12(2):e6944. doi: 10.7759/cureus.6944. PMID: 32190495; PMCID: PMC7067354.
Kishimoto H, Noguchi K, Takaoka K. Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Jpn Dent Sci Rev. 2019 Nov;55(1):95-102. doi: 10.1016/j.jdsr.2018.09.002. Epub 2019 May 17. PMID: 31193410; PMCID: PMC6526304.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56. doi: 10.1016/j.joms.2014.04.031. Epub 2014 May 5. Erratum in: J Oral Maxillofac Surg. 2015 Jul;73(7):1440. Erratum in: J Oral Maxillofac Surg. 2015 Sep;73(9):1879. PMID: 25234529.
Soutome S, Otsuru M, Hayashida S, Murata M, Yanamoto S, Sawada S, Kojima Y, Funahara M, Iwai H, Umeda M, Saito T. Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci Rep. 2021 Aug 26;11(1):17226. doi: 10.1038/s41598-021-96480-8. PMID: 34446755; PMCID: PMC8390686.
Dixon RB, Tricker ND, Geretto LP: Bone turnover in early canine mandible and tibia. J Dent Res. 1997; 76: 336.
Kwon TG. Risk Factors for Medication-Related Osteonecrosis of the Jaw. In: Medication-related osteonecrosis of the jaws. Bisphosphonates, Denosumab, and New Agents Springer Publishing. 2015; 32-3.
Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Feb;127(2):117-135. doi: 10.1016/j.oooo.2018.09.008. Epub 2018 Oct 9. PMID: 30393090.
Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015 May;44(5):568-85. doi: 10.1016/j.ijom.2015.01.026. Epub 2015 Feb 26. PMID: 25726090.
Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: A literature review. J Oral Biosci. 2019 Jun;61(2):99-104. doi: 10.1016/j.job.2019.03.005. Epub 2019 May 15. PMID: 31109863.
Querrer R, Ferrare N, Melo N, Stefani CM, Dos Reis PED, Mesquita CRM, Borges GA, Leite AF, Figueiredo PT. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review. Support Care Cancer. 2021 Jun;29(6):2811-2820. doi: 10.1007/s00520-020-05855-6. Epub 2020 Nov 2. Erratum in: Support Care Cancer. 2021 Mar 18;: PMID: 33140246.
Yao S, Ding X, Rong G, Zhou J, Zhang B. Association Between Malignant Diseases and Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis. J Craniofac Surg. 2022 Oct 3. doi: 10.1097/SCS.0000000000009033. Epub ahead of print. PMID: 36184756.